Management of Helicobacter pylori–Related Diseases, An Issue of Gastroenterology Clinics of North America, 1st Edition
Author :
Akiko Shiotani
Date of Publication: 09/2015
Helicobacter pylori (H. pylori) infection is a worldwide disease with a significant morbidity and mortality; it is the leading cause of non-ulcer dyspepsia, peptic ulcers and gastric tumors, including low-grade mucosa-associated lymphoid tissue-lymph ...view more
Helicobacter pylori (H. pylori) infection is a worldwide disease with a significant morbidity and mortality; it is the leading cause of non-ulcer dyspepsia, peptic ulcers and gastric tumors, including low-grade mucosa-associated lymphoid tissue-lymphoma and adenocarcinoma. In addition, it has also been recognized that the interaction between H. pylori and non-steroidal, anti-inflammatory drugs is damaging to the gastroduodenal mucosa. H. pylori treatment still remains a challenge for physicians, since no current first-line therapy is able to cure the infection in all treated patients. This issue will serve to update gastroenterologists on current therapies, evaluation and management of disease progression, and the future of management of H. pylori infection.
Helicobacter pylori (H. pylori) infection is a worldwide disease with a significant morbidity and mortality; it is the leading cause of non-ulcer dyspepsia, peptic ulcers and gastric tumors, including low-grade mucosa-associated lymphoid tissue-lymphoma and adenocarcinoma. In addition, it has also been recognized that the interaction between H. pylori and non-steroidal, anti-inflammatory drugs is damaging to the gastroduodenal mucosa. H. pylori treatment still remains a challenge for physicians, since no current first-line therapy is able to cure the infection in all treated patients. This issue will serve to update gastroenterologists on current therapies, evaluation and management of disease progression, and the future of management of H. pylori infection.
Bring it with you - The Bookshelf app allows you to access books on your laptop, tablet or mobile, so your ebooks go where ever you are - online or offline.
Take notes - Highlight, bookmark and take notes and highlights automatically stay in sync no matter where you make them.
Listen to eBooks - When you need to go screenless, the Text-to-speech tool will read your book aloud.
Powerful search - The searching capabilities allow you to search keywords through all your eBooks, the entire Bookshelf Library and well as on Wikipedia.
Ecological - Manage your environmental impact with paperless books.
How to read your VitalSource eBooks
Purchase your VitalSource eBook on the Elsevier Health site
https://www.uk.elsevierhealth.com/management-of-helicobacter-pylori-related-diseases-an-issue-of-gastroenterology-clinics-of-north-america-9780323395656.html90444Management of Helicobacter pylori–Related Diseases, An Issue of Gastroenterology Clinics of North Americahttps://www.uk.elsevierhealth.com/media/catalog/product/9/7/9780323395656_6.jpg60.7963.99GBPInStock/Medicine and Surgery/Gastroenterology & Hepatology/Books/Clinics Review Articles100425255039561283917453100005145120Helicobacter pylori (H. pylori) infection is a worldwide disease with a significant morbidity and mortality; it is the leading cause of non-ulcer dyspepsia, peptic ulcers and gastric tumors, including low-grade mucosa-associated lymphoid tissue-lymphoma and adenocarcinoma. In addition, it has also been recognized that the interaction between H. pylori and non-steroidal, anti-inflammatory drugs is damaging to the gastroduodenal mucosa. H. pylori treatment still remains a challenge for physicians, since no current first-line therapy is able to cure the infection in all treated patients. This issue will serve to update gastroenterologists on current therapies, evaluation and management of disease progression, and the future of management of H. pylori infection. Helicobacter pylori (H. pylori) infection is a worldwide disease with a significant morbidity and mortality; it is the leading cause of non-ulcer dyspepsia, peptic ulcers and gastric tumors, including low-grade mucosa-associated lymphoid tissue-lymphoma and adenocarcinoma. In addition, it has also been recognized that the interaction between H. pylori and non-steroidal, anti-inflammatory drugs is damaging to the gastroduodenal mucosa. H. pylori treatment still remains a challenge for physicians, since no current first-line therapy is able to cure the infection in all treated patients. This issue will serve to update gastroenterologists on current therapies, evaluation and management of disease progression, and the future of management of H. pylori infection.00add-to-cart97803233956562015ProfessionalBy Akiko Shiotani20151Book152w x 229h (6.00" x 9.00")Elsevier010 Sep 2015PRINT ON DEMAND - DELIVERY CAN TAKE UP TO 10 DAYSBy <STRONG>Akiko Shiotani</STRONG>ClinicsThe Clinics: Internal MedicineNoNoNoNoPlease SelectPlease SelectPlease Select
